Highmark Inc., one of the largest Blue Cross Blue Shield plans in the United States, said Saturday it would stop covering laparoscopic power morcellation because it could spread cancer in women undergoing gynecological surgery. The procedure involved a bladed device that cut up fibroid tumors and if cancer is present, distributes the cells over a wider area.
The Wall Street Journal said Highmark is the first insurer to stop coverage. The Food and Drug Administration said in April it would re-evaluate the safety of the procedure and advised doctors against using it in the interim. Johnson & Johnson (NYSE:JNJ) suspended sales of the device and Thursday re...
Also read: What it's like to meet terrorists